In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.
…
continue reading
![Artwork](/static/images/128pixel.png)
1
S12 Ep15: Inavolisib Has a Favorable Risk-Benefit Profile for PIK3CA-Mutant, HR+ Metastatic Breast Cancer: With Komal Jhaveri, MD, FACP
14:58
14:58
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب
14:58In today’s episode, supported by Genentech, we had the pleasure of speaking with Komal Jhaveri, MD, FACP, about the clinical use of inavolisib (Itovebi) for patients with hormone receptor (HR)–positive, PIK3CA-mutated, locally advanced or metastatic breast cancer. Dr Jhaveri is section head of the Endocrine Therapy Research Program, clinical direct…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
S12 Ep14: FDA Approval Insights: Dato-DXd for HR+/HER2-Negative Metastatic Breast Cancer: With Aditya Bardia, MD, MPH, FASCO
6:33
6:33
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب
6:33In our exclusive interview, Dr Bardia discussed the significance of this approval, pivotal findings from the phase 3 TROPION-Breast01 trial (NCT05104866), the clinical relevance of being able to improve progression-free survival and quality of life with Dato-DXd compared with standard chemotherapy, and key considerations for sequencing antibody-dru…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
S12 Ep13: Ponatinib-Based Regimens Strengthen the Ph+ ALL Treatment Paradigm: With Mark B. Geyer, MD, and Elias Jabbour, MD
30:35
30:35
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب
30:35In today’s episode, supported by Takeda, we had the pleasure of speaking with Mark B. Geyer, MD, and Elias Jabbour, MD, about updates in the management of Philadelphia chromosome (Ph)–positive acute lymphoblastic leukemia (ALL). Dr Geyer is the Adolescent and Young Adult Program leader and the Adult Lymphoblastic Leukemia Program leader in the Leuk…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
S12 Ep12: Advances in RAS-Mutant PDAC Management Emphasize the Importance of Biomarker Testing: With Heinz-Josef Lenz, MD
9:26
9:26
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب
9:26In today’s episode, supported by Revolution Medicines, we had the pleasure of speaking with Heinz-Josef Lenz, MD, about RAS mutations in pancreatic ductal adenocarcinoma (PDAC). Dr Lenz is a professor of medicine at the Keck School of Medicine of the University of Southern California (USC), as well as the J. Terrence Lanni Chair in Gastrointestinal…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
S12 Ep11: How Academia and Industry Intersect to Improve Oncology Research and Patient Care: With D. Ross Camidge, MD, PhD; and Tim Eisen, MB BChir, PhD
1:02:05
1:02:05
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب
1:02:05Drs Camidge and Eisen discussed Dr Eisen's dual career in academia and industry. Growing up in London, he pursued medicine, excelling in cell pathology at University College London, and later specialized in oncology at Cambridge. He joined Roche in 2020. Dr Eisen emphasized the importance of aligning academic and clinical strengths, advocating for …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
S12 Ep10: Olverembatinib Research Signals a New Era of CP-CML Management: With Elias Jabbour, MD
5:49
5:49
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب
5:49In today’s episode, supported by Ascentage Pharma, we had the pleasure of speaking with Elias Jabbour, MD, a professor in the Department of Leukemia in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston. In our exclusive interview, Dr Jabbour discussed the 1.5-year follow-up data from a phase 1b trial (N…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
S12 Ep9: How Second Primary Cancer Risk Factors Into CAR T-Cell Therapy Considerations: With Saurabh Dahiya, MD, FACP; and Shyam A. Patel, MD, PhD
21:08
21:08
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب
21:08Drs Dahiya and Patel discussed the pathobiology of SPCs that develop after CAR T-cell therapy, potential SPC prevention strategies, and how SPC research may help optimize CAR T-cell product development in the future.بقلم OncLive® On Air
…
continue reading
![Artwork](/static/images/128pixel.png)
1
S12 Ep8: How are Antibody-Drug Conjugates Shaping the NSCLC Treatment Paradigm? With David Gerber, MD
27:06
27:06
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب
27:06In today’s episode, we had the pleasure of speaking with David Gerber, MD, a professor in the Department of Internal Medicine at the University of Texas Southwestern Medical Center, a member of its Division of Hematology/Oncology, and co-director of Education and Training for the Harold C. Simmons Comprehensive Cancer Center in Dallas. In our exclu…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
S12 Ep7: Blinatumomab-Based Regimens Enhance and Refine the B-ALL Treatment Paradigm: With Ryan Cassaday, MD
19:06
19:06
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب
19:06In today’s episode, supported by Amgen, we had the pleasure of speaking with Ryan Cassaday, MD, an associate professor in the Clinical Research Division at the Fred Hutchinson Cancer Center and an associate professor in the Division of Hematology and Oncology at the University of Washington School of Medicine in Seattle, Washington. In our exclusiv…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
S12 Ep6: FDA Approval Insights: Subcutaneous Nivolumab for Advanced Solid Tumors: With Roxana S. Dronca, MD
10:56
10:56
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب
10:56In today’s episode, supported by Bristol Myers Squibb, we had the pleasure of speaking with Roxana S. Dronca, MD, about the FDA approval of subcutaneous nivolumab and hyaluronidase-nvhy (Opdivo Qvantig; subcutaneous nivolumab) for advanced or metastatic solid tumors. Dr Dronca is a professor of oncology, a consultant in the Division of Hematology/O…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
S12 Ep5: MedNews Week Advances Global Oncology Education and Combats Misinformation: With Chandler Park, MD; and Yan Leyfman, MD
19:31
19:31
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب
19:31In this episode of Oncology Unplugged, a podcast series from OncLive and MedNews Week, podcast host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, and Yan Leyfman, MD, a resident physician at Mount Sinai in New York, New York, discussed the origins and mission of MedNews Week, a global platform designed …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
S12 Ep4: Oncogene Analysis Identifies Clinically Relevant Gene Copy Number Gain Thresholds in NSCLC: With Alec Watson, MD
30:25
30:25
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب
30:25In today’s episode, we had the pleasure of speaking with Alec Watson, MD, a thoracic oncology fellow in the School of Medicine in the Division of Medical Oncology at the University of Colorado Anschutz Medical Campus in Aurora. In our exclusive interview, Dr Watson discussed the rationale for and key findings from a retrospective analysis examining…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
S12 Ep3: Clinical Practice Insights Reveal the Complexity of Lymphoma Subtypes and Advances in First-Line Treatments: With Chandler Park, MD; and Joshua Brody, MD
23:08
23:08
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب
23:08In this Oncology Unplugged discussion, Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, and Joshua Brody, MD, director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute at Mount Sinai in New York, New York, explored the heterogeneity of lymphoma subtypes and the evolution of treatment par…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
S12 Ep2: Pembrolizumab Plus Preoperative Radiotherapy and Surgery Improves DFS in Soft-Tissue Sarcoma: With Yvonne Mowery, MD, PhD
16:23
16:23
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب
16:23In today’s episode, we had the pleasure of speaking with Yvonne Mowery, MD, PhD, about the phase 2 SU2C-SARC032 trial (NCT03092323) investigating the addition of pembrolizumab to preoperative radiotherapy and surgery in patients with soft-tissue sarcoma. Dr Mowey is a physician scientist and an associate professor of radiation oncology at the Unive…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
S12 Ep1: FDA Approval Insights: Zenocutuzumab for NRG1+ Pancreatic Adenocarcinoma and NSCLC: With Alison Schram, MD
5:59
5:59
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب
5:59In today’s episode, supported by Merus, we had the pleasure of speaking with Alison Schram, MD, about the FDA approval of zenocutuzumab-zbco (Bizengri) for patients with previously treated advanced pancreatic adenocarcinoma or non–small cell lung cancer (NSCLC) harboring NRG1 gene fusions. Dr Schram is an assistant attending physician at Memorial S…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
S11 Ep50: DESTINY-Breast06 Data Demonstrate the Role of T-DXd in HER2-Low and -Ultralow Breast Cancer: With Chandler Park, MD; and Guiseppe Curigliano, MD, PhD
18:33
18:33
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب
18:33In this episode of Oncology Unplugged, a podcast series from MedNews Week, host Chandler Park, MD, a medical oncologist at the Norton Cancer Institute in Louisville, Kentucky, was joined by Guiseppe Curigliano, MD, PhD, a full professor of medical oncology at the University of Milan, as well as the director of the Early Drug Development Division an…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
S11 Ep49: Explore the Evolving Role of BTK Inhibitors in CLL: With Alexey Danilov, MD, PhD; and Susan M. O'Brien, MD
23:38
23:38
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب
23:38In today’s episode, supported by BeiGene, Alexey Danilov, MD, PhD, hosted a discussion with Susan M. O'Brien, MD, about key data updates with BTK inhibitors in patients with chronic lymphocytic leukemia (CLL) that were presented at the 2024 ASH Annual Meeting. Dr Danilov is the Marianne and Gerhard Pinkus Professor of Early Clinical Therapeutics, t…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
S11 Ep48: FDA Approval Insights: Zanidatamab in Pretreated, HER2+ Biliary Tract Cancer
14:11
14:11
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب
14:11In today’s episode, supported by Jazz Pharmaceuticals, we had the pleasure of speaking with James J. Harding, MD, director of Early Drug Development at Memorial Sloan Kettering Cancer Center, about the FDA approval of zanidatamab-hrii (Ziihera) for patients with HER2-positive metastatic biliary tract cancer. In our exclusive interview, Dr Harding d…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
S11 Ep47: Exploring Luspatercept's Role in Anemia Management for Lower-Risk MDS: Insights From Dr. Jorge Cortes
8:12
8:12
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب
8:12بقلم OncLive® On Air
…
continue reading
![Artwork](/static/images/128pixel.png)
1
S11 Ep46: The Evolving Role of ctDNA in Guiding Adjuvant Chemotherapy Decisions in CRC: Insights from Stacey A. Cohen, MD
17:51
17:51
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب
17:51In our exclusive interview, Dr Cohen provided insights into the evolving role of circulating tumor DNA (ctDNA) in clinical decision-making for patients with colorectal cancer (CRC), particularly through findings from the CIRCULATE-Japan GALAXY trial (UMIN000039205). She highlighted how ctDNA has emerged as a strong prognostic factor for recurrence …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
S11 Ep45: Asciminib and Ponatinib Sit at the Forefront of Advances in CML Management: Insights From Onyee Chan, MD; and Bradley D. Hunter, MD
13:42
13:42
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب
13:42In our exclusive interview, Drs Chan and Hunter discussed the integration of asciminib (Scemblix) as a first-line therapy for patients with CML, optimal treatment sequencing in CML management, and how findings from the phase 2 OPTIC trial (NCT02467270) have influenced ponatinib (Iclusig) dosing strategies in patients with chronic-phase disease. The…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
S11 Ep44: Explore MRD Dynamics With Isa-VRd in Newly Diagnosed Multiple Myeloma: Insights From Philippe Moreau, MD
8:19
8:19
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب
8:19In our exclusive interview, Dr Moreau discussed key findings from an analysis of minimal residual disease negativity dynamics from IMROZ and the potential future implications of these findings for patients with newly diagnosed multiple myeloma who receive treatment with Isa-VRd.بقلم OncLive® On Air
…
continue reading
![Artwork](/static/images/128pixel.png)
1
S11 Ep43: Zanubrutinib Leads the Way for Advancements in CLL Management: With Mazyar Shadman, MD, MPH
14:58
14:58
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب
14:58In today’s episode, supported by BeiGene, we had the pleasure of speaking with Mazyar Shadman, MD, MPH, about updates in zanubrutinib (Brukinsa)–focused research in chronic lymphocytic leukemia (CLL) that were presented at the 2024 ASH Annual Meeting. Dr Shadman is an associate professor in the Clinical Research Division and the medical director of…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
S11 Ep41: Unpacking Key Data From the 2024 ASH Annual Meeting: With Andre Goy, MD
23:27
23:27
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب
23:27In today’s episode, we had the pleasure of speaking with Andre Goy, MD, about key updates from the 2024 ASH Annual Meeting. Dr Goy is physician in chief of Hackensack Meridian Health Oncology Care Transformation Services, as well as the chairman, chief physician officer, and chief of the Lymphoma Division at the John Theurer Cancer Center at Hacken…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
S11 Ep42: Exploring Lasofoxifene Plus Abemaciclib in ESR1+ Breast Cancer: Insights from ELAINE-3 With Sagar D. Sardesai, MBBS
4:55
4:55
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب
4:55Sagar D. Sardesai, MBBS, discusses the phase 3 ELAINE-3 trial evaluating lasofoxifene plus abemaciclib in ESR1-mutant, ER+/HER2- metastatic breast cancer.بقلم OncLive® On Air
…
continue reading
![Artwork](/static/images/128pixel.png)
1
S11 Ep41: Explore Findings With Nivolumab Plus AVD in Advanced-Stage Classic Hodgkin Lymphoma: With Alex F. Herrera, MD
15:14
15:14
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب
15:14In today’s episode, we had the pleasure of speaking with Alex F. Herrera, MD, about key safety and efficacy findings from the phase 3 SWOG S1826 trial (NCT03907488) evaluating nivolumab (Opdivo) plus doxorubicin, vinblastine, and dacarbazine (N+AVD) vs brentuximab vedotin (BV) plus AVD (BV+AVD) in adolescent and adult patients with stage III or IV …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
S11 Ep41: Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD
16:47
16:47
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب
16:47In this episode of Oncology Unplugged, a podcast series from MedNews Week, host Chandler Park, MD, a medical oncologist at the Norton Cancer Institute in Louisville, Kentucky, was rejoined by Stephen Liu, MD, a thoracic oncologist and the Head of Developmental Therapeutics at Georgetown University’s Lombardi Comprehensive Cancer Center in Washingto…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
S11 Ep40: T-DXd Steadily Transforms the NSCLC Treatment Paradigm: With Misako Nagasaka, MD, PhD
10:29
10:29
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب
10:29In today’s episode, supported by Daiichi Sankyo, we had the pleasure of speaking with Misako Nagasaka, MD, PhD, about the use of fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) in patients with non–small cell lung cancer (NSCLC). Dr Nagasaka is an associate professor in the Division of Hematology and Oncology and the Division of Medicine at the Un…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
S11 Ep40: How to Optimize Patient Selection for Multiple Myeloma Therapies: With Binod Dhakal, MD; and Muhamed Baljevic, MD
36:36
36:36
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب
36:36In today’s episode, we had the pleasure of speaking with Binod Dhakal, MD, and Muhamed Baljevic, MD, about updates regarding patient identification for optimal multiple myeloma treatment. Dr Dhakal is an associate professor of medicine in the Division of Hematology at the Medical College of Wisconsin in Milwaukee. Dr Baljevic is an associate profes…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
S11 Ep38: Pancreatic Cancer Research Surfaces Treatment Developments and Challenges: With John Strickler, MD
13:16
13:16
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب
13:16In today’s episode, supported by Revolution Medicines, we had the pleasure of speaking with John Strickler, MD, about key considerations for pancreatic cancer management in honor of Pancreatic Cancer Awareness Month, which is observed every November. Dr Strickler is a professor of medicine in the Division of Medical Oncology, associate director of …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
S11 Ep38: FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL
8:29
8:29
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب
8:29In today’s episode, we had the pleasure of speaking with Paul J. Shaughnessy, MD, about the FDA approval of obecabtagene autoleucel (obe-cel; Aucatzyl) for patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Dr Shaughnessy is the medical director of the Adult Blood and Marrow Stem Cell Transplant Program at Met…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
S11 Ep39: Explore the Latest Treatment Updates in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen V. Liu, MD
11:19
11:19
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب
11:19Drs Park and Liu explore advancements in the management of EGFR-mutated NSCLC, highlighting clinical trial updates shaping current treatment strategies.بقلم OncLive® On Air
…
continue reading
![Artwork](/static/images/128pixel.png)
1
S11 Ep38: Long-Term Data Solidify the Role of Zanubrutinib in R/R CLL: With Alexey Danilov, MD, PhD; and Nicole Lamanna, MD
12:46
12:46
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب
12:46In today’s episode, supported by BeiGene, Alexey Danilov, MD, PhD, hosted a discussion with Nicole Lamanna, MD, about the use of zanubrutinib (Brukinsa) in patients with chronic lymphocytic leukemia (CLL). Dr Danilov is the Marianne and Gerhard Pinkus Professor of Early Clinical Therapeutics, the medical director of the Early Phase Therapeutics Pro…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
S11 Ep37: Trastuzumab Deruxtecan Advances HER2+ Gynecologic Cancer Care: With Susana M. Campos, MD, MPH
7:59
7:59
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب
7:59OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. In today’s episode, we had th…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
S11 Ep36: HPV16-Targeted Immunotherapy Is Set to Personalize HNSCC Management: With Kevin Harrington, MD, PhD, FRCP, FRCR, FRSB
16:56
16:56
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب
16:56In today’s episode, supported by PDS Biotech, we had the pleasure of speaking with Kevin Harrington, MD, PhD, FRCP, FRCR, FRSB, about the role of PDS0101 (Versamune HPV) in patients with human papillomavirus type 16 (HPV16)–positive head and neck squamous cell carcinoma (HNSCC). Dr Harrington is head of the Division of Radiotherapy and Imaging at T…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
S11 Ep35: FDA Approval Insights: Zolbetuximab for CLDN18.2+ HER2-Negative Gastric and GEJ Adenocarcinoma
10:06
10:06
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب
10:06On October 18, 2024, the FDA approved zolbetuximab plus fluoropyrimidine- and platinum-containing chemotherapy for the frontline treatment of adult patients with locally advanced unresectable or metastatic, HER2-negative, CLDN18.2-positive gastric or GEJ adenocarcinoma. This regulatory decision was backed by findings from the phase 3 SPOTLIGHT (NCT…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
S11 Ep34: Relacorilant Plus Nab-Paclitaxel Carves New Avenues of Platinum-Resistant Ovarian Cancer Care: With Premal Thaker, MD, MS
9:48
9:48
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب
9:48In today’s episode, supported by Corcept Therapeutics, we had the pleasure of speaking with Premal Thaker, MD, MS, about the use of the selective glucocorticoid receptor modulator relacorilant (CORT125134) in patients with ovarian cancer. Dr Thaker is the David G. and Lynn Mutch Distinguished Professor of Obstetrics and Gynecology, as well as the d…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
S11 Ep33: Explore Emerging Breast Cancer Treatment Trends With Kevin Kalinsky, MD, MS
11:31
11:31
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب
11:31In our exclusive interview, Dr Kalinsky discussed his top takeaways from the 2024 ASCO Annual Meeting and 2024 ESMO Congress, as well as where he sees the field of breast cancer headed in the future.بقلم OncLive® On Air
…
continue reading
![Artwork](/static/images/128pixel.png)
1
S11 Ep32: Review Key Genitourinary Cancer Data From the 2024 ESMO Congress With Chandler Park, MD
11:50
11:50
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب
11:50In Oncology Unplugged, a podcast series from MedNews Week, host Chandler Park, MD, a medical oncologist at the Norton Cancer Institute in Louisville, Kentucky, talks through key updates in genitourinary cancer research from the 2024 ESMO Congress. In this episode, Dr Park highlights potentially practice-changing data in prostate, kidney, and bladde…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
S11 Ep31: How to Use Toripalimab Plus Chemotherapy in Nasophryngeal Carcinoma: With Tarek Mekhail, MD, MSC, FRCSI, FRCSEd
9:41
9:41
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب
9:41In today’s episode, supported by Coherus Biosciences, we had the pleasure of speaking with Tarek Mekhail, MD, MSC, FRCSI, FRCSEd, about the use of toripalimab-tpzi (Loqtorz) in patients with nasopharyngeal carcinoma. Dr Mekhail is the medical director of the Thoracic Cancer Program and the Associate Executive Director at the AdventHealth Cancer Ins…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
S11 Ep30: SUNLIGHT QOL Data Show Positive Outcomes With T rifluridine-Tipiracil Plus Bevacizumab in CRC : With Joleen Hubbard, MD
10:38
10:38
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب
10:38In today’s episode, supported by Taiho Pharmaceutical, we had the pleasure of speaking with Joleen Hubbard, MD, about practice-changing updates to the colorectal cancer (CRC) treatment paradigm. Dr Hubbard is a medical oncologist at Allina Health Cancer Institute in Minneapolis, Minnesota. In our exclusive interview, Dr Hubbard discussed key effica…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
S11 Ep29: Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD
20:23
20:23
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب
20:23In this episode of the Oncology Unplugged series, Chandler Park, MD, a genitourinary medical oncologist at Norton Cancer Institute in Louisville, Kentucky, hosted a conversation with Vivek Subbiah, MD, a medical oncologist and chief of Early-Phase Drug Development at Sarah Cannon Research Institute in Nashville, Tennessee. Dr Subbiah, an internatio…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
S11 Ep28: Liquid Biopsy Ushers in a New Era of NSCLC Biomarker Testing: With David R. Gandara, MD
11:29
11:29
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب
11:29In today’s episode, we had the pleasure of speaking with David R. Gandara, MD, about biomarker testing in lung cancer. Dr Gandara is the chief medical officer of the International Society of Liquid Biopsy, the co-director of the Center for Experimental Therapeutics in Cancer, and the senior advisor to the director at the University of California Da…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
S11 Ep27: Delve into Recent NCCN Guideline Updates for Hepatobiliary and CRC Management: With Alan P. Venook, MD
11:33
11:33
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب
11:33In today’s episode, we had the pleasure of speaking with Alan P. Venook, MD, about recent updates to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for gastrointestinal (GI) cancers. Dr Venook holds the Madden Family Distinguished Professorship in Medical Oncology and Translational Research and is a professor in the D…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
S11 Ep26: Phase 1 Trials Provide Oncology Fellows With Valuable Clinical Research Experience: With Samuel A. Kareff, MD, MPH
14:08
14:08
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب
14:08In today’s episode, we had the pleasure of speaking with Samuel A. Kareff, MD, MPH, about the intersections between early-phase clinical research and meaningful mentorship experiences during oncology/hematology fellowship. Dr Kareff is a medical oncologist and hematologist at the Eugene M. and Christine E. Lynn Cancer Institute, part of Baptist Hea…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
S11 Ep25: FDA Approval Insights: Denileukin Diftitox in Relapsed/Refractory CTCL
8:17
8:17
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب
8:17In today’s episode, supported by Citius Pharmaceuticals, we had the pleasure of speaking with Francine Foss, MD, to discuss the FDA approval of denileukin diftitox-cxdl (Lymphir) for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma (CTCL) who have received 1 or more prior systemic therapies. Dr Foss is a professor of med…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
S11 Ep24: How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD
17:21
17:21
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب
17:21Dr Patil emphasized the significance of the phase 3 CROWN trial (NCT03052608), which compared lorlatinib (Lorbrena) with crizotinib (Xalkori) in patients with ALK-positive metastatic NSCLC. With a hazard ratio of 0.19 (95% CI, 0.13-0.27) for progression-free survival, the trial demonstrated lorlatinib’s superior intracranial control and long-term e…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
S11 Ep23: Navigating Myelofibrosis: Updates for Community Hematologist Oncologists
25:38
25:38
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب
25:38In today’s episode, supported by Sobi, we had the pleasure of speaking with Aaron T. Gerds, MD, MS, and James K. McCloskey, MD, about myelofibrosis treatment advances. Dr Gerds is an assistant professor in the Department of Medicine in the School of Medicine, as well as a member of the Developmental Therapeutics Program at the Case Comprehensive Ca…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
S11 Ep22: FDA Approval Insights: Vorasidenib in IDH1/2+ Grade 2 Astrocytoma and Oligodendroglioma
12:28
12:28
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب
12:28In today’s episode, supported by Servier Pharmaceuticals, we had the pleasure of speaking with Jennie W. Taylor, MD, MPH, about the FDA approval of vorasidenib (Voranigo) for patients with IDH-positive grade 2 astrocytoma or oligodendroglioma. Dr Taylor is an associate professor of clinical neurology at the University of California, San Francisco (…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
S11 Ep21: Updated VISION Trial Data Showcase the Efficacy of Tepotinib in MET + NSCLC: With Martin Dietrich, MD
11:59
11:59
التشغيل لاحقا
التشغيل لاحقا
قوائم
إعجاب
احب
11:59In our exclusive interview, Dr Dietrich discussed key efficacy findings from the 18-month follow-up of the phase 2 VISION trial (NCT02864992), which evaluated the efficacy of tepotinib (Tepmetko) in patients with non–small cell lung cancer harboring MET exon 14 skipping mutations. Additionally, Dr Dietrich emphasized important safety considerations…
…
continue reading